Terms: = Leukemia AND CACNA1D, CCHL1A2, Cav1_3, CACNL1A2, CACN4, CACH3, ENSG00000157388, 776 AND Treatment
23 results:
1. Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.
Zhou JY; Wang S; Yuan HL; Xu YJ; Huang XB; Gao SJ; Zhang YC; Zhou F; Liu Y; Song XM; Cai Y; Liu XL; Luo Y; Yang LX; Yang JM; Wang LB; Li YH; Huang R; Wang SQ; Zhou M; Dong YJ; Wang Q; Zhang X; Feng YM; Du X; Ling W; Zhu H; Zhu ZM; Chen XL; Wang SY; Meng FK; Bi KH; Huang N; Jiang M; Niu T; Ji J; Wan DM; Bian ZL; Chen Y; Liu L; Yan XQ; Yang X; Yi H; Wei XD; Li X; Cheng Q; Yuan CL; Wang W; Zhou YH; Ye BD; Ding J; Wu YJ; Huang QS; Zhu XL; Chen YH; He Y; Wang FR; Zhang YY; Mo XD; Han W; Wang JZ; Wang Y; Chen H; Zhao XY; Chang YJ; Liu KY; Huang XJ; Zhang XH
Am J Hematol; 2023 Sep; 98(9):1394-1406. PubMed ID: 37366294
[TBL] [Abstract] [Full Text] [Related]
2. Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models.
Singh D; Gupta M; Sarwat M; Siddique HR
Crit Rev Oncol Hematol; 2022 Aug; 176():103751. PubMed ID: 35752426
[TBL] [Abstract] [Full Text] [Related]
3. The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.
Huang HH; Chen CM; Wang CY; Hsu WW; Chen HM; Ko BS; Hsiao FY
PLoS One; 2022; 17(1):e0261871. PubMed ID: 35061709
[TBL] [Abstract] [Full Text] [Related]
4. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
Thomas JW; Jamy O; Shah MV; Vachhani P; Go RS; Goyal G
Leuk Res; 2022 Jan; 112():106770. PubMed ID: 34920340
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacological mechanism of mylabris in the treatment of leukemia based on bioinformatics and systematic pharmacology.
Zhan H; Bai Y; Lv Y; Zhang X; Zhang L; Deng S
Bioengineered; 2021 Dec; 12(1):3229-3239. PubMed ID: 34224300
[TBL] [Abstract] [Full Text] [Related]
6. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Pleyer C; Ali MA; Cohen JI; Tian X; Soto S; Ahn IE; Gaglione EM; Nierman P; Marti GE; Hesdorffer C; Lotter J; Superata J; Wiestner A; Sun C
Blood; 2021 Jan; 137(2):185-189. PubMed ID: 33259596
[TBL] [Abstract] [Full Text] [Related]
7. Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea.
Kwon J; Kim SY; Yeob KE; Han HS; Lee KH; Shin DW; Kim YY; Park JH; Park JH; Kawachi I
Cancer Med; 2020 Aug; 9(15):5335-5344. PubMed ID: 32491262
[TBL] [Abstract] [Full Text] [Related]
8. Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes.
Alhashim N; Aljurf M; Hassanein M; Chaudhri N; Hashmi S; El-Gohary G; Alsharif F; Alsermani M; Alhumaid M; Beihany AA; Shaheen M; Hanbali A; Alfraih F; Mohamed S; Alzahrani H; Elhassan T; Eldali A; Rasheed W; Ahmed S; Almohareb F; El Fakih R
Bone Marrow Transplant; 2018 Jul; 53(7):838-843. PubMed ID: 29371685
[TBL] [Abstract] [Full Text] [Related]
9. Sepsis and Acute Myeloid leukemia: A Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals.
Malik IA; Cardenas-Turanzas M; Gaeta S; Borthakur G; Price K; Cortes J; Nates JL
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e27-e32. PubMed ID: 28844403
[TBL] [Abstract] [Full Text] [Related]
10. Advances in the Classification and treatment of Mastocytosis: Current Status and Outlook toward the Future.
Valent P; Akin C; Hartmann K; Nilsson G; Reiter A; Hermine O; Sotlar K; Sperr WR; Escribano L; George TI; Kluin-Nelemans HC; Ustun C; Triggiani M; Brockow K; Gotlib J; Orfao A; Schwartz LB; Broesby-Olsen S; Bindslev-Jensen C; Kovanen PT; Galli SJ; Austen KF; Arber DA; Horny HP; Arock M; Metcalfe DD
Cancer Res; 2017 Mar; 77(6):1261-1270. PubMed ID: 28254862
[TBL] [Abstract] [Full Text] [Related]
11. Childhood cancer survival in Switzerland (1976-2013): Time-trends and predictors.
Schindler M; Belle FN; Grotzer MA; von der Weid NX; Kuehni CE;
Int J Cancer; 2017 Jan; 140(1):62-74. PubMed ID: 27632765
[TBL] [Abstract] [Full Text] [Related]
12. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.
Parry HM; Damery S; Hudson C; Maurer MJ; Cerhan JR; Pachnio A; Begum J; Slager SL; Fegan C; Man S; Pepper C; Shanafelt TD; Pratt G; Moss PA
Am J Hematol; 2016 Aug; 91(8):776-81. PubMed ID: 27124884
[TBL] [Abstract] [Full Text] [Related]
13. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract] [Full Text] [Related]
14. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.
Verdecchia A; Francisci S; Brenner H; Gatta G; Micheli A; Mangone L; Kunkler I;
Lancet Oncol; 2007 Sep; 8(9):784-96. PubMed ID: 17714993
[TBL] [Abstract] [Full Text] [Related]
15. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
Campbell PJ; Scott LM; Buck G; Wheatley K; East CL; Marsden JT; Duffy A; Boyd EM; Bench AJ; Scott MA; Vassiliou GS; Milligan DW; Smith SR; Erber WN; Bareford D; Wilkins BS; Reilly JT; Harrison CN; Green AR; ; ;
Lancet; 2005 Dec; 366(9501):1945-53. PubMed ID: 16325696
[TBL] [Abstract] [Full Text] [Related]
16. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
[TBL] [Abstract] [Full Text] [Related]
17. Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients.
Chatzidakis K; Goulas A; Athanassiadou-Piperopoulou F; Fidani L; Koliouskas D; Mirtsou V
Pediatr Blood Cancer; 2006 Aug; 47(2):147-51. PubMed ID: 16123993
[TBL] [Abstract] [Full Text] [Related]
18. Amount of DNA in plasma and cancer risk: a prospective study.
Gormally E; Hainaut P; Caboux E; Airoldi L; Autrup H; Malaveille C; Dunning A; Garte S; Matullo G; Overvad K; Tjonneland A; Clavel-Chapelon F; Boffetta P; Boeing H; Trichopoulou A; Palli D; Krogh V; Tumino R; Panico S; Bueno-de-Mesquita HB; Peeters PH; Lund E; Gonzalez CA; Martinez C; Dorronsoro M; Barricarte A; Tormo MJ; Quiros JR; Berglund G; Hallmans G; Day NE; Key TJ; Veglia F; Peluso M; Norat T; Saracci R; Kaaks R; Riboli E; Vineis P
Int J Cancer; 2004 Sep; 111(5):746-9. PubMed ID: 15252845
[TBL] [Abstract] [Full Text] [Related]
19. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor I; Dwilewicz-Trojaczek J; Boguradzki P; Konopka L; Ceglarek B; Sułek J; Kuliczkowski K; Wołowiec D; Stella-Hołowiecka B; Skotnicki AB; Nowak W; Moskwa-Sroka B; Dmoszyńska A; Calbecka M
Leukemia; 2001 Oct; 15(10):1510-6. PubMed ID: 11587207
[TBL] [Abstract] [Full Text] [Related]
20. Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies.
Van Gool SW; Van Kerschaver E; Brock P; Pottel H; Hulstaert F; Vanmechelen E; Uyttebroeck A; Van De Voorde A; Vanderstichele H
Leukemia; 2000 Dec; 14(12):2076-84. PubMed ID: 11187896
[TBL] [Abstract] [Full Text] [Related]
[Next]
